Celgene settles Revlimid patent litigation

23 December 2015

Shares of US biotech major Celgene (Nasdaq: CELG) rose 9% to $121.03 in after-hours trading on Tuesday, after it reported a patent settlement – or pay-for-delay deal - for its best-selling drug Revlimid (lenalidomide).

Celgene announced the settlement of litigation with India’s Natco Pharma and Natco’s US partner, Arrow International Ltd, and Arrow’s parent company, Watson Laboratories (a wholly-owned subsidiary of Allergan [NYSE: ACT]), relating to patents for Revlimid, a multiple myeloma treatment, sales of which the company recently said will hit around $5.8 billion for the full-year 2015.

As part of the settlement, the parties will file Consent Judgments with the US District Court for the District of New Jersey that enjoin Natco from marketing generic lenalidomide before the expiration of the patents-in-suit, except as provided for in the settlement, as described below.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK